Clinuvel Pharmaceuticals Ltd (CLVLF)
Clinuvel Pharmaceuticals Ltd is a biopharmaceutical company headquartered in Melbourne, Australia, and listed on OTC Markets as common stock. The company develops and commercializes treatments for patients with genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and other international markets. Its lead drug candidate is SCENESSE, a systemic photoprotective therapy being developed for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). Clinuvel’s development pipeline also includes CUV9900, PR
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-CLVL.F
|
$9.84
|
67.1% Upside
|
Bargain
|
Not available
|
Not available
|
Great
|
0.6%
|
12.3x
|
1.5x
|
4.4x
|
296.1 M
|
114.8 M
|
0.5%
|
87.0%
|
24.0
|
7.4%
|
104.1%
|
